Foreign Pharmaceutical Plants Fail FDA Inspections at Nearly Twice the Domestic Rate

Washington, Thursday, 12 March 2026.
A new study reveals a critical supply chain vulnerability: foreign pharmaceutical facilities fail FDA inspections at up to 1.8 times the rate of domestic plants amid surging U.S. imports.